Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute leukemia patients. Here we shall discuss the biological and clinical observations which indicate that this innovative therapeutic approach may play a role in the management of minimal residual disease.
Has IL2 a role in the management of minimal residual disease for acute leukemia? / Foa, Roberto; Meloni, Giovanna; Guarini, Anna; Mandelli, Franco; Gavosto, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 6 SUPPL 4:(1992), pp. 92-94.
Has IL2 a role in the management of minimal residual disease for acute leukemia?
FOA, Roberto;MELONI, Giovanna;GUARINI, Anna;MANDELLI, Franco;
1992
Abstract
Based on pre-clinical findings and on more recent preliminary in vivo data it has been suggested that immunotherapy with Interleukin 2 (IL2) may be employed in the treatment of acute leukemia patients. Here we shall discuss the biological and clinical observations which indicate that this innovative therapeutic approach may play a role in the management of minimal residual disease.File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
